Abstract:A "tug-of-war" between kinases and phosphatases establishes the phosphorylation states of proteins. While serine and threonine phosphorylation can be catalyzed by more than 400 protein kinases, the majority of serine and threonine dephosphorylation is carried out by seven phosphoprotein phosphatases (PPPs). The PPP family consists of protein phosphatases 1 (PP1), 2A (PP2A), 2B (PP2B), 4 (PP4), 5 (PP5), 6 (PP6), and 7 (PP7). The imbalance in numbers between serine- and threonine-directed kinases and phosphatases led to the early belief that PPPs are unspecific and that kinases are the primary determinants of protein phosphorylation. However, it is now clear that PPPs achieve specificity through association with noncatalytic subunits to form multimeric holoenzymes, which expands the number of functionally distinct signaling entities to several hundred. Although there has been great progress in deciphering signaling by kinases, much less is known about phosphatases.We have developed a chemical proteomic strategy for the systematic interrogation of endogenous PPP catalytic subunits and their interacting proteins, including regulatory and scaffolding subunits (the "PPPome"). PP1, PP2A, PP4, PP5, and PP6 were captured using an immobilized, specific but nonselective PPP inhibitor microcystin-LR (MCLR), followed by protein identification by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in a single analysis. Here, we combine this approach of phosphatase inhibitor bead profiling and mass spectrometry (PIB-MS) with label-free and tandem mass tag (TMT) quantification to map the PPPome in human cancer cell lines, mouse tissues, and yeast species, through which we identify cell- and tissue-type-specific PPP expression patterns and discover new PPP interacting proteins.

Dual Function of Protein Phosphatase 5 (PPP5C): an Emerging Therapeutic Target for Drug Discovery.

An Artificial Protein Modulator Reprogramming Neuronal Protein Functions

Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer.

Targeting phosphatases: From molecule design to clinical trials

Targeting PTPs with small molecule inhibitors in cancer treatment

A Quantitative Chemical Proteomic Strategy for Profiling Phosphoprotein Phosphatases from Yeast to Humans

Structural Feature and Biological Function of PPP2R5C Gene

Recent Advances in the Development of Allosteric Protein Tyrosine Phosphatase Inhibitors for Drug Discovery.

Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B

Druggable targets of protein tyrosine phosphatase Family, viz. PTP1B, SHP2, Cdc25, and LMW-PTP: Current scenario on medicinal Attributes, and SAR insights

Small-molecule Modulators Targeting SHP2 for Cancer Therapy

PP2A-Mediated Anticancer Therapy.

Targeted Protein Posttranslational Modifications by Chemically Induced Proximity for Cancer Therapy

Allosteric Activation of Protein Phosphatase 5 with Small Molecules

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Altering phosphorylation in cancer through PP2A modifiers

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

Targeting RAS Phosphorylation in Cancer Therapy: Mechanisms and Modulators

Protein Phosphatase 2a: Its Structure, Function and Activity Regulation

Mapping the substrate landscape of protein phosphatase 2A catalytic subunit PPP2CA

A Comprehensive Overview of PPM1B: from Biological Functions to Diseases